Inhibition of microtubule assembly by a complex of actin and antitumor macrolide aplyronine A. 2013

Masaki Kita, and Yuichiro Hirayama, and Kozo Yoneda, and Kota Yamagishi, and Takumi Chinen, and Takeo Usui, and Eriko Sumiya, and Motonari Uesugi, and Hideo Kigoshi
Graduate School of Pure and Applied Sciences and ‡Graduate School of Life and Environmental Sciences, University of Tsukuba , 1-1-1 Tennodai, Tsukuba 305-8571, Japan.

Aplyronine A (ApA) is a marine natural product that shows potent antitumor activity. While both ApA and ApC, a derivative of ApA that lacks a trimethylserine ester moiety, inhibit actin polymerization in vitro to the same extent, only ApA shows potent cytotoxicity. Therefore, the molecular targets and mechanisms of action of ApA in cells have remained unclear. We report that ApA inhibits tubulin polymerization in a hitherto unprecedented way. ApA forms a 1:1:1 heterotrimeric complex with actin and tubulin, in association with actin synergistically binding to tubulin, and inhibits tubulin polymerization. Tubulin-targeting agents have been widely used in cancer chemotherapy, but there are no previous descriptions of microtubule inhibitors that also bind to actin and affect microtubule assembly. ApA inhibits spindle formation and mitosis in HeLa S3 cells at 100 pM, a much lower concentration than is needed for the disassembly of the actin cytoskeleton. The results of the present study indicate that ApA represents a rare type of natural product, which binds to two different cytoplasmic proteins to exert highly potent biological activities.

UI MeSH Term Description Entries
D008870 Microtubules Slender, cylindrical filaments found in the cytoskeleton of plant and animal cells. They are composed of the protein TUBULIN and are influenced by TUBULIN MODULATORS. Microtubule
D008938 Mitosis A type of CELL NUCLEUS division by means of which the two daughter nuclei normally receive identical complements of the number of CHROMOSOMES of the somatic cells of the species. M Phase, Mitotic,Mitotic M Phase,M Phases, Mitotic,Mitoses,Mitotic M Phases,Phase, Mitotic M,Phases, Mitotic M
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000199 Actins Filamentous proteins that are the main constituent of the thin filaments of muscle fibers. The filaments (known also as filamentous or F-actin) can be dissociated into their globular subunits; each subunit is composed of a single polypeptide 375 amino acids long. This is known as globular or G-actin. In conjunction with MYOSINS, actin is responsible for the contraction and relaxation of muscle. F-Actin,G-Actin,Actin,Isoactin,N-Actin,alpha-Actin,alpha-Isoactin,beta-Actin,gamma-Actin,F Actin,G Actin,N Actin,alpha Actin,alpha Isoactin,beta Actin,gamma Actin
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001688 Biological Products Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay. Biologic,Biologic Drug,Biologic Product,Biological,Biological Drug,Biological Medicine,Biological Product,Biologics,Biopharmaceutical,Natural Product,Natural Products,Biologic Drugs,Biologic Medicines,Biologic Pharmaceuticals,Biologic Products,Biological Drugs,Biological Medicines,Biologicals,Biopharmaceuticals,Products, Biological,Drug, Biologic,Drug, Biological,Drugs, Biologic,Drugs, Biological,Medicine, Biological,Medicines, Biologic,Medicines, Biological,Pharmaceuticals, Biologic,Product, Biologic,Product, Biological,Product, Natural
D014404 Tubulin A microtubule subunit protein found in large quantities in mammalian brain. It has also been isolated from SPERM FLAGELLUM; CILIA; and other sources. Structurally, the protein is a dimer with a molecular weight of approximately 120,000 and a sedimentation coefficient of 5.8S. It binds to COLCHICINE; VINCRISTINE; and VINBLASTINE. alpha-Tubulin,beta-Tubulin,delta-Tubulin,epsilon-Tubulin,gamma-Tubulin,alpha Tubulin,beta Tubulin,delta Tubulin,epsilon Tubulin,gamma Tubulin
D018942 Macrolides A group of often glycosylated macrocyclic compounds formed by chain extension of multiple PROPIONATES cyclized into a large (typically 12, 14, or 16)-membered lactone. Macrolides belong to the POLYKETIDES class of natural products, and many members exhibit ANTIBIOTIC properties. Macrolide

Related Publications

Masaki Kita, and Yuichiro Hirayama, and Kozo Yoneda, and Kota Yamagishi, and Takumi Chinen, and Takeo Usui, and Eriko Sumiya, and Motonari Uesugi, and Hideo Kigoshi
September 1996, Journal of biochemistry,
Masaki Kita, and Yuichiro Hirayama, and Kozo Yoneda, and Kota Yamagishi, and Takumi Chinen, and Takeo Usui, and Eriko Sumiya, and Motonari Uesugi, and Hideo Kigoshi
October 2021, Chemical communications (Cambridge, England),
Masaki Kita, and Yuichiro Hirayama, and Kozo Yoneda, and Kota Yamagishi, and Takumi Chinen, and Takeo Usui, and Eriko Sumiya, and Motonari Uesugi, and Hideo Kigoshi
December 2017, Bioorganic & medicinal chemistry,
Masaki Kita, and Yuichiro Hirayama, and Kozo Yoneda, and Kota Yamagishi, and Takumi Chinen, and Takeo Usui, and Eriko Sumiya, and Motonari Uesugi, and Hideo Kigoshi
May 1983, FEBS letters,
Masaki Kita, and Yuichiro Hirayama, and Kozo Yoneda, and Kota Yamagishi, and Takumi Chinen, and Takeo Usui, and Eriko Sumiya, and Motonari Uesugi, and Hideo Kigoshi
April 2022, Organic & biomolecular chemistry,
Masaki Kita, and Yuichiro Hirayama, and Kozo Yoneda, and Kota Yamagishi, and Takumi Chinen, and Takeo Usui, and Eriko Sumiya, and Motonari Uesugi, and Hideo Kigoshi
May 1981, Canadian journal of biochemistry,
Masaki Kita, and Yuichiro Hirayama, and Kozo Yoneda, and Kota Yamagishi, and Takumi Chinen, and Takeo Usui, and Eriko Sumiya, and Motonari Uesugi, and Hideo Kigoshi
April 2005, Developmental cell,
Masaki Kita, and Yuichiro Hirayama, and Kozo Yoneda, and Kota Yamagishi, and Takumi Chinen, and Takeo Usui, and Eriko Sumiya, and Motonari Uesugi, and Hideo Kigoshi
January 2006, Bioconjugate chemistry,
Masaki Kita, and Yuichiro Hirayama, and Kozo Yoneda, and Kota Yamagishi, and Takumi Chinen, and Takeo Usui, and Eriko Sumiya, and Motonari Uesugi, and Hideo Kigoshi
May 1980, Biochemistry,
Masaki Kita, and Yuichiro Hirayama, and Kozo Yoneda, and Kota Yamagishi, and Takumi Chinen, and Takeo Usui, and Eriko Sumiya, and Motonari Uesugi, and Hideo Kigoshi
March 2006, Journal of molecular biology,
Copied contents to your clipboard!